Figure 2.
Assessment of circulating level of miRNAs in anthracycline-treated patient. Relative expression of circulating (A) miR-423, (B) miR-499, (C) miR-126, (D) mIR-29a and (E) mIR-34a, assessed by qRT-PCR analysis. Values represent means ± SEM. *p < 0.05 vs. Control, **p < 0.01 vs. Control, #p < 0.05 vs. Baseline, ##p < 0.01 vs. Baseline, +p < 0.05 vs. 3 months, ++p < 0.01 vs. 3 months. Control (n = 17) and patients with breast cancer (n = 17) at baseline, 3 months and 6 months.